Ataraxis AI is launching Ataraxis ARC, a prospective study designed to evaluate AI model predictions and link them with real-world cancer patient outcomes, with initial enrollment of 1,000 patients across top cancer centers.
Public source
Publisher name
Public post
We are launching Ataraxis ARC, a prospective study designed to evaluate Ataraxis's AI model predictions and link them with real-world short- and long-term cancer patient…
Company
Ataraxis AI
Transforming Cancer Care with AI Precision Medicine
- Industry
- Artificial Intelligence
- Location
- New York, US
- Company size
- 11–50 employees
About Ataraxis AI
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.
See moreLatest activity
Latest activity from Ataraxis AI
7 signals
Research & Knowledge
Ataraxis AI is launching Ataraxis ARC, a prospective study designed to evaluate AI model predictions and link them with real-world cancer patient outcomes, with initial enrollment of 1,000 patients across top cancer centers.
Research & Knowledge
Ataraxis AI is launching a prospective registry study evaluating its AI prediction in more than just breast cancer.
Research & Knowledge
Ataraxis AI launched Ataraxis ARC, a large prospective study evaluating how clinical AI helps build truly personalized treatment plans and impacts outcomes for real patients.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Association of Cancer Care Centers
Association of Cancer Care Centers is launching an AI in Precision Oncology call for submissions to explore the responsible, evidence-based application of AI in cancer care.
Research & Knowledge
Cure51
Cure51 published a Rosalind Study combining multiple layers of patient data, including genomics, transcriptomics, pathology, clinical history, and multi-omics insights, to integrate complex datasets and identify patterns for AI-driven treatment prediction.
Research & Knowledge
Radiology News
Radiology News highlights Dr. Alexander Pearson exploring how AI and high-performance computing could extract clinically useful insights from cancer care data, including CT scans, pathology images, and molecular data.
Research & Knowledge
Oncogene Cancer Research
Oncogene Cancer Research published a study in European Radiology testing an AI system on real-world UK lung cancer screening data, achieving an 83.5% fully automated success rate and 91.8% performance for uncomplicated cases.
Research & Knowledge
Addario Lung Cancer Medical Institute (ALCMI)